Key facts
- It has raised $5.0M; the latest was Seed Round ($4.0M) in Dec 2025.
- Notable investors include Y Combinator, Techstars, Lightspeed Venture Partners, Gaingels, StartX (US) — 23 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for Nephrogen
- ·The full record, as it builds
Funding rounds
No funding rounds for Nephrogen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nephrogen
Developer of gene delivery vectors designed to address challenges in creating genomic medicines for kidney and pancreatic diseases. The company integrates artificial intelligence and screening to engineer gene delivery vectors that improve efficiency, reduce immune response, and lower costs of genomic medicine, enabling researchers and clinicians to advance curative genomic therapies and improve patient outcomes.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2015
- Employees
- 6
- Website
- nephrogenbiotech.com/
- Ownership
- Privately Held (backing)
Nephrogen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nephrogen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nephrogen in its N-PORT filings yet. We sweep new filings monthly.